MRI Interventions' ClearPoint Neuro Intervention System Recently Profiled by Boston's ABC-TV Affiliate

MRI Interventions' ClearPoint Neuro Intervention System Recently Profiled by
Boston's ABC-TV Affiliate

TV Segment and Article Focus on How ClearPoint is Giving Hope to Patients

IRVINE, Calif., Dec. 16, 2013 (GLOBE NEWSWIRE) -- The ClearPoint^® Neuro
Intervention System developed by MRI Interventions, Inc. (OTCQB:MRIC) was
featured December 10 in a television segment and article reported by the
ABC-TV affiliate in Boston (WCVB-TV).

The report, filmed in part at Brigham and Women's Hospital in Boston,
highlighted how the ClearPoint System enables neurosurgeons to view the inside
of patients' brains in real time while they operate, using intraoperative MRI
imaging. The report—which spotlights one female patient whose tremor was
alleviated following a ClearPoint-guided surgery—notes that the technology is
being used in surgical procedures to treat epilepsy, pediatric dystonia and
Parkinson's disease, and is being used in clinical trials to deliver
investigational drugs for conditions such as brain cancer.

To watch the television segment and read the accompanying article, please
visit the following link:

http://www.wcvb.com/health/new-brain-surgery-technology-giving-hope-to-patients/-/9848730/23419416/-/uwigknz/-/index.html

About the ClearPoint System

The ClearPoint^® Neuro Intervention System is a navigation platform designed
to allow real-time, direct visualization during minimally-invasive
neurosurgical procedures. ClearPoint software works with MRI to assist
surgeons in planning a target and trajectory, and the SmartFrame^® targeting
device enables the MRI-guided alignment and insertion of surgical instruments.
The ClearPoint System has been used to enable asleep deep brain stimulation
procedures, laser ablation therapy and brain biopsy, and is currently involved
in five clinical trials investigating direct drug delivery in the brain.

The ClearPoint SmartFlow^® cannula is presently FDA-cleared for injection of
cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the
ventricles during intracranial procedures. Delivery of other therapeutic
agents using the SmartFlow cannula is investigational.

About MRI Interventions, Inc.

Founded in 1998, MRI Interventions is creating innovative platforms for
performing the next generation of minimally invasive surgical procedures in
the brain and heart. Utilizing a hospital's existing MRI suite, the company's
FDA-cleared and CE-marked ClearPoint System is designed to enable a range of
minimally invasive procedures in the brain. MRI Interventions has a
co-development and co-distribution agreement with Brainlab, a leader in
software-driven medical technology, relating to the ClearPoint system. In
partnership with Siemens Healthcare, MRI Interventions is developing the
ClearTrace^® System to enable MRI-guided catheter ablations to treat cardiac
arrhythmias, including atrial fibrillation. Building on the imaging power of
MRI, the company's interventional platforms strive to improve patient care
while reducing procedure costs and times. MRI Interventions is also working
with Boston Scientific Corporation to incorporate its MRI-safety technologies
into Boston Scientific's implantable leads for cardiac and neurological
applications. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking statements
by their nature address matters that, to different degrees, are uncertain and
involve risk. Uncertainties and risks may cause MRI Interventions' actual
results and the timing of events to differ materially from those expressed in
or implied by MRI Interventions' forward-looking statements. Particular
uncertainties and risks include, among others: demand and market acceptance of
our products; our ability to successfully expand our sales and clinical
support capabilities; availability of third party reimbursement; the
sufficiency of our cash resources to maintain planned commercialization
efforts and research and development programs; future actions of the FDA or
any other regulatory body that could impact product development, manufacturing
or sale; our ability to protect and enforce our intellectual property rights;
our dependence on collaboration partners; the impact of competitive products
and pricing; and the impact of the commercial and credit environment on us and
our customers and suppliers. More detailed information on these and additional
factors that could affect MRI Interventions' actual results are described in
MRI Interventions' filings with the Securities and Exchange Commission,
including, without limitation, MRI Interventions' Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on November 13, 2013.
Except as required by law, MRI Interventions undertakes no obligation to
publicly update or revise any forward-looking statements contained in this
press release to reflect any change in MRI Interventions' expectations or any
change in events, conditions or circumstances on which any such statements are
based.

CONTACT: MRI Interventions, Inc.
         David Carlson, CFO, 901-522-9300
        
         Dian Griesel Int'l
         Susan Forman/Laura Radocaj
         212-825-3210

MRI Interventions, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.